Dr. Yayi He is the recepient of the IASLC / Boehringer Ingelheim Chinese Research Fellowship Award for 2014-2016. The goal of this fellowship is to reward scientific excellence and to encourage innovative and collaborative investigation in the fields of lung cancer prevention, diagnosis and translational research with a potential impact on the management of lung cancer. The pool of applications are reviewed and scored by an international committee of experts who send their recommendations to the board of directors for final selection.
Dr. He comes from Shanghai Pulmonary Hospital under the montorship of Dr. Caicun Zhou and will conduct her research followship at the University of Colorado Anschutz Medical Campus under the guidance of Dr. Fred R. Hirsch. Her research will investigate the molecular mechanisms of acquired resistance to afatinib (BIBW2992) in lung adenocarcinoma with HER2 mutations using in vitro and in vivo models. She will also explore how to overcome acquired resistance to afatinib as well as potential biomarkers associated with the acquired resistance.
Dr. He has numerous years of experience in lung cancer research focusing on mechanisms of drug resistance, personalized therapy and translational medicine. She notes that with the application of new targeted-therapies and the identification of novel driver oncogenes, lung cancer patients have obtained more options and better quality of life, however, many challenges are still unmet. Most lung cancer patients are still diagnosed in late stage, the 5-year survival rate remains low and drug resistance remains a universal problem; thus more effort and team work are required.
She is grateful to receive the award and states "The Boehringer Ingelheim / IASLC Chinese Research Fellowhisp Award Project provides a precious opportunity for lots of Chinese doctors and researchers" and "I am sure that a solid foundation will be set for my further studies of translational research in lung cancer".